--- title: "Arvinas (ARVN) news: layoffs and buyback" url: "https://aibio.space/companies/arvinas/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ARVN layoffs and buyback news: Arvinas cuts about 15% of staff, authorizes $100 million buyback. Arvinas, Inc. (NASDAQ: ARVN), United States." --- ARVN Arvinas, Inc. NASDAQ · United States # Arvinas (ARVN) news ARVN layoffs and buyback news Distress · 2025-09-17 ## [Arvinas to cut about 15% of staff, seek vepdegestrant partner; approves $100 million buyback](https://aibio.space/news/arvinas-cut-about-15-percent-staff-seek-vepdegestrant-partner-approves/) Arvinas said on September 17, 2025 that it will cut its workforce by a further 15%, mainly in vepdegestrant commercialization roles, and that it will seek a third party to take over the drug with Pfizer. The same day its board authorized a buyback of up to $100 million, and the filing does not give the cash balance on which that depends. ## Latest Arvinas news 1. 2025-09-17 Distress [Arvinas cuts about 15% of staff, authorizes $100 million buyback](https://aibio.space/news/arvinas-cuts-about-15-percent-staff-authorizes-100-million-buyback/) The company and Pfizer have agreed to out-license vepdegestrant commercialization rights and have begun looking for a partner. Arvinas expects about $4.5 million in workforce costs. 2. 2025-05-01 Distress [Arvinas cuts workforce by about 33% and drops two Phase 3 vepdegestrant trials with Pfizer](https://aibio.space/news/arvinas-cuts-workforce-about-33-percent-drops-two-phase-3/) Arvinas expects about $10 million in severance and termination costs, mostly in the second quarter of 2025. It and Pfizer removed two planned Phase 3 combination trials from the joint development plan. 3. 2025-01-22 Distress [Arvinas subsidiary ends New Haven lab lease, effective December 31, 2024](https://aibio.space/news/arvinas-subsidiary-ends-new-haven-lab-lease-effective-december-31-2024/) Under the January 15, 2025 agreement, Arvinas Operations owes no rent after the termination date if it clears the space by January 21, 2025. ## Arvinas at a glance - **Ticker**: ARVN - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $567.9 million ### Related companies - [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) NASDAQ: DMAC - [Elicio Therapeutics](https://aibio.space/companies/elicio-therapeutics/) NASDAQ: ELTX - [NeOnc Technologies Holdings](https://aibio.space/companies/neonc-technologies/) NASDAQ: NTHI - [UMeWorld](https://aibio.space/companies/umeworld/) OTC: UMEW - [Disc Medicine](https://aibio.space/companies/disc-medicine/) NASDAQ: IRON - [Aspira Women's Health](https://aibio.space/companies/aspira-women-s-health/) OTC: AWHL - [Scribe Therapeutics](https://aibio.space/companies/scribe-therapeutics/) NASDAQ: SCTX - [AFFYMAX INC](https://aibio.space/companies/affymax/) OTC: AFFY ### Also on NASDAQ - [Milestone Pharmaceuticals](https://aibio.space/companies/milestone-pharmaceuticals/) MIST - [Verastem](https://aibio.space/companies/verastem/) VSTM - [IN8bio](https://aibio.space/companies/in8bio/) INAB - [Cryoport](https://aibio.space/companies/cryoport/) CYRX - [Altimmune](https://aibio.space/companies/altimmune/) ALT - [PRO DEX INC](https://aibio.space/companies/pro-dex/) PDEX ## Arvinas annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$262.6 million](https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/) | [$263.4 million](https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/) | | Research and development | [$285.2 million](https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/) | [$348.2 million](https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/) | | Net income (loss) | [-$80.8 million](https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/) | [-$198.9 million](https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/) | | Cash from operations | [-$273.8 million](https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/) | [-$259.3 million](https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/) | | Cash and equivalents | [$142.9 million](https://www.sec.gov/Archives/edgar/data/1655759/000162828026052554/) | [$100.5 million](https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/) | | Short-term investments | [$542.5 million](https://www.sec.gov/Archives/edgar/data/1655759/000162828026052554/) | [$938.9 million](https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $94.3 million, plus short-term investments of $473.6 million, $567.9 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Arvinas Has Arvinas cut staff? Our latest story on this, dated Sep 17, 2025: "Arvinas cuts about 15% of staff, authorizes $100 million buyback". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/arvinas-cuts-about-15-percent-staff-authorizes-100-million-buyback/). Does Arvinas have a share buyback? Our latest story on this, dated Sep 17, 2025: "Arvinas to cut about 15% of staff, seek vepdegestrant partner; approves $100 million buyback". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/arvinas-cut-about-15-percent-staff-seek-vepdegestrant-partner-approves/). What is the ticker symbol of Arvinas? Arvinas, Inc. trades under the ticker ARVN on NASDAQ. Where is Arvinas listed? Arvinas, Inc. is listed on NASDAQ. What is the SEC CIK of Arvinas? The SEC Central Index Key (CIK) for Arvinas, Inc. is 1655759. Its filings are on SEC EDGAR. How many shares does Arvinas have outstanding? 65,386,191 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-04. Which country or territory is Arvinas listed under? Our directory records Arvinas, Inc. under United States. What does Arvinas do? Our directory classifies Arvinas, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Arvinas? The ISIN recorded for Arvinas, Inc. is US04335A1051. Does aibio.space cover Arvinas? aibio.space lists Arvinas, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Arvinas incorporated? SEC records list its state or country of incorporation as DE. What was Arvinas's revenue last year? $262.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Arvinas profitable? Arvinas, Inc. reported a net loss of $80.8 million for the fiscal year ended Dec 31, 2025, and used $273.8 million of cash in operations, per its annual report to the SEC. How much does Arvinas spend on research and development? $285.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Arvinas have? $567.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Arvinas Members talk about Arvinas (ARVN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Arvinas, newest first. Each line links the filing it comes from. 1. 2025-09-17 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000147/arvn-20250917.htm) 2. 2025-05-01 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000081/arvn-20250331xexx991.htm) 3. 2025-01-22 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). [Source](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000006/arvn-20250115.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ARVN on TradingView](https://www.tradingview.com/symbols/NASDAQ-ARVN/). ## SEC filings and registration - **SEC name**: Arvinas, Inc. - **CIK**: 1655759 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ARVN (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer - **Business address**: 395 WINCHESTER AVE, NEW HAVEN, CT, 06511 - **Phone**: 203-535-1456 - **Shares outstanding**: 65,386,191 as of 2026-07-31 (10-Q filed 2026-08-04) - **Former names**: ARVINAS INC.; ARVINAS HOLDING COMPANY, LLC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1655759/000162828026052554/arvn-20260630.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/arvn-20260804.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1655759/000162828026045520/arvn-20260624.htm) filed 2026-06-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1655759/000162828026044627/arvn-20260622.htm) filed 2026-06-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1655759/000162828026043559/arvn-20260611.htm) filed 2026-06-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1655759/000162828026039818/arvn-20260602.htm) filed 2026-06-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1655759/000162828026033875/arvn-20260512.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1655759/000162828026033874/arvn-20260511.htm) filed 2026-05-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001655759), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Arvinas, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ARVN, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Arvinas, Inc. - **Ticker**: ARVN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US04335A1051 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ARVN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/arvinas/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Arvinas (ARVN) news: layoffs and buyback", 2026-10-31, https://aibio.space/companies/arvinas/